Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, August 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 42 Mendeley

Summary Policy documents Dimensions citations

So far, Dimensions has found 8 publications that cite this research output.

8

The most recent citing publications are shown below. View all 8 publications that cite this research output on Dimensions.

Cost-Effectiveness Analysis of Long-acting Injectable Once-monthly of Aripiprazole Compared with Long-acting Injectable Once-monthly Paliperidone Palmitate for the Treatment of Stable Schizophrenia Patients in Thailand

Article in Siriraj Medical Journal (October 2023)

Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study

Article in Frontiers in Psychiatry (August 2023)

A 10-year mirror-image study of effectiveness and cost of long-acting paliperidone palmitate injectable in patients with schizophrenia or schizoaffective disorder

Article in Psychiatry Research (April 2022)